737 related articles for article (PubMed ID: 27527741)
21. Long-term effect of sustained virological response on hepatocellular carcinoma in patients with hepatitis C in Canada.
Janjua NZ; Chong M; Kuo M; Woods R; Wong J; Yoshida EM; Sherman M; Butt ZA; Samji H; Cook D; Yu A; Alvarez M; Tyndall M; Krajden M
J Hepatol; 2017 Mar; 66(3):504-513. PubMed ID: 27818234
[TBL] [Abstract][Full Text] [Related]
22. Early Fibrosis but Late Tumor Stage and Worse Outcomes in Hepatocellular Carcinoma Patients Without Hepatitis B or Hepatitis C.
Hsu PY; Hsu CT; Yeh ML; Huang CF; Huang CI; Liang PC; Lin YH; Hsieh MY; Wei YJ; Hsieh MH; Dai CY; Lin ZY; Chen SC; Huang JF; Yu ML; Chuang WL
Dig Dis Sci; 2020 Jul; 65(7):2120-2129. PubMed ID: 31722058
[TBL] [Abstract][Full Text] [Related]
23. The occurrence of hepatocellular carcinoma in different risk stratifications of clinically noncirrhotic nonalcoholic fatty liver disease.
Lee TY; Wu JC; Yu SH; Lin JT; Wu MS; Wu CY
Int J Cancer; 2017 Oct; 141(7):1307-1314. PubMed ID: 28509327
[TBL] [Abstract][Full Text] [Related]
24. Impact of diabetes mellitus on incidence of hepatocellular carcinoma in chronic hepatitis C patients treated with interferon-based antiviral therapy.
Hung CH; Lee CM; Wang JH; Hu TH; Chen CH; Lin CY; Lu SN
Int J Cancer; 2011 May; 128(10):2344-52. PubMed ID: 20669224
[TBL] [Abstract][Full Text] [Related]
25. Rate of incidence of hepatocellular carcinoma in patients with compensated viral cirrhosis.
Chiaramonte M; Stroffolini T; Vian A; Stazi MA; Floreani A; Lorenzoni U; Lobello S; Farinati F; Naccarato R
Cancer; 1999 May; 85(10):2132-7. PubMed ID: 10326690
[TBL] [Abstract][Full Text] [Related]
26. Incidence, aetiology and related comorbidities of cirrhosis: a Swedish population-based cohort study.
Vaz J; Eriksson B; Strömberg U; Buchebner D; Midlöv P
BMC Gastroenterol; 2020 Apr; 20(1):84. PubMed ID: 32245414
[TBL] [Abstract][Full Text] [Related]
27. Incidence and risk factors for hepatocellular carcinoma after solid organ transplantation.
Hoffmann CJ; Subramanian AK; Cameron AM; Engels EA
Transplantation; 2008 Sep; 86(6):784-90. PubMed ID: 18813102
[TBL] [Abstract][Full Text] [Related]
28. Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: a prospective cohort study.
Carrat F; Fontaine H; Dorival C; Simony M; Diallo A; Hezode C; De Ledinghen V; Larrey D; Haour G; Bronowicki JP; Zoulim F; Asselah T; Marcellin P; Thabut D; Leroy V; Tran A; Habersetzer F; Samuel D; Guyader D; Chazouilleres O; Mathurin P; Metivier S; Alric L; Riachi G; Gournay J; Abergel A; Cales P; Ganne N; Loustaud-Ratti V; D'Alteroche L; Causse X; Geist C; Minello A; Rosa I; Gelu-Simeon M; Portal I; Raffi F; Bourliere M; Pol S;
Lancet; 2019 Apr; 393(10179):1453-1464. PubMed ID: 30765123
[TBL] [Abstract][Full Text] [Related]
29. Diabetes mellitus, metabolic syndrome and obesity are not significant risk factors for hepatocellular carcinoma in an HBV- and HCV-endemic area of Southern Taiwan.
Chen CT; Chen JY; Wang JH; Chang KC; Tseng PL; Kee KM; Chen PF; Tsai LS; Chen SC; Lin SC; Lu SN
Kaohsiung J Med Sci; 2013 Aug; 29(8):451-9. PubMed ID: 23906236
[TBL] [Abstract][Full Text] [Related]
30. Increased risk of hepatocellular carcinoma among patients with hepatitis C cirrhosis and diabetes mellitus.
Veldt BJ; Chen W; Heathcote EJ; Wedemeyer H; Reichen J; Hofmann WP; de Knegt RJ; Zeuzem S; Manns MP; Hansen BE; Schalm SW; Janssen HL
Hepatology; 2008 Jun; 47(6):1856-62. PubMed ID: 18506898
[TBL] [Abstract][Full Text] [Related]
31. Eradication of Hepatitis C Virus Infection in Patients With Cirrhosis Reduces Risk of Liver and Non-Liver Complications.
Nahon P; Bourcier V; Layese R; Audureau E; Cagnot C; Marcellin P; Guyader D; Fontaine H; Larrey D; De Lédinghen V; Ouzan D; Zoulim F; Roulot D; Tran A; Bronowicki JP; Zarski JP; Leroy V; Riachi G; Calès P; Péron JM; Alric L; Bourlière M; Mathurin P; Dharancy S; Blanc JF; Abergel A; Serfaty L; Mallat A; Grangé JD; Attali P; Bacq Y; Wartelle C; Dao T; Benhamou Y; Pilette C; Silvain C; Christidis C; Capron D; Bernard-Chabert B; Zucman D; Di Martino V; Thibaut V; Salmon D; Ziol M; Sutton A; Pol S; Roudot-Thoraval F;
Gastroenterology; 2017 Jan; 152(1):142-156.e2. PubMed ID: 27641509
[TBL] [Abstract][Full Text] [Related]
32. Risk of Hepatocellular Cancer in Patients With Non-Alcoholic Fatty Liver Disease.
Kanwal F; Kramer JR; Mapakshi S; Natarajan Y; Chayanupatkul M; Richardson PA; Li L; Desiderio R; Thrift AP; Asch SM; Chu J; El-Serag HB
Gastroenterology; 2018 Dec; 155(6):1828-1837.e2. PubMed ID: 30144434
[TBL] [Abstract][Full Text] [Related]
33. Skeletal muscle fat deposition is associated with hepatocellular carcinoma development in patients with chronic liver disease.
Tachi Y; Kozuka A; Hirai T; Kojima Y; Ishizu Y; Honda T; Kuzuya T; Hayashi K; Ishigami M; Goto H
Nutrition; 2018 Oct; 54():83-88. PubMed ID: 29753174
[TBL] [Abstract][Full Text] [Related]
34. Association between complicated liver cirrhosis and the risk of hepatocellular carcinoma in Taiwan.
Hung TH; Liang CM; Hsu CN; Tai WC; Tsai KL; Ku MK; Wang JW; Tseng KL; Yuan LT; Nguang SH; Yang SC; Wu CK; Hsu PI; Wu DC; Chuah SK
PLoS One; 2017; 12(7):e0181858. PubMed ID: 28742130
[TBL] [Abstract][Full Text] [Related]
35. The risk of end stage liver disease and hepatocellular carcinoma among persons infected with hepatitis C virus: publication bias?
Goodgame B; Shaheen NJ; Galanko J; El-Serag HB
Am J Gastroenterol; 2003 Nov; 98(11):2535-42. PubMed ID: 14638360
[TBL] [Abstract][Full Text] [Related]
36. Surveillance factors change outcomes in patients with hepatocellular carcinoma due to chronic hepatitis C virus infection in New Zealand.
Schauer C; van Rijnsoever M; Gane E
J Viral Hepat; 2019 Dec; 26(12):1372-1376. PubMed ID: 31323163
[TBL] [Abstract][Full Text] [Related]
37. Proton pump inhibitors are associated with accelerated development of cirrhosis, hepatic decompensation and hepatocellular carcinoma in noncirrhotic patients with chronic hepatitis C infection: results from ERCHIVES.
Li DK; Yan P; Abou-Samra AB; Chung RT; Butt AA
Aliment Pharmacol Ther; 2018 Jan; 47(2):246-258. PubMed ID: 29105111
[TBL] [Abstract][Full Text] [Related]
38. Incidence of hepatocellular carcinoma in outpatients with cirrhosis in Brazil: A 10-year retrospective cohort study.
Appel-da-Silva MC; Miozzo SA; Dossin IA; Tovo CV; Branco F; de Mattos AA
World J Gastroenterol; 2016 Dec; 22(46):10219-10225. PubMed ID: 28028370
[TBL] [Abstract][Full Text] [Related]
39. Aspartate aminotransferase to platelet ratio index and sustained virologic response are associated with progression from hepatitis C associated liver cirrhosis to hepatocellular carcinoma after treatment with pegylated interferon plus ribavirin.
Ng KJ; Tseng CW; Chang TT; Tzeng SJ; Hsieh YH; Hung TH; Huang HT; Wu SF; Tseng KC
Clin Interv Aging; 2016; 11():1035-41. PubMed ID: 27536084
[TBL] [Abstract][Full Text] [Related]
40. Prediction of hepatocellular carcinoma development by aminotransferase to platelet ratio index in primary biliary cholangitis.
Cheung KS; Seto WK; Fung J; Mak LY; Lai CL; Yuen MF
World J Gastroenterol; 2017 Nov; 23(44):7863-7874. PubMed ID: 29209127
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
